In this issue: EMCDDA scientific award 2016 | Lisbon Addictions 2017 | New report on drug‑related hospital emergencies | Grounds for hope in treating hepatitis C | EC proposes amendment to EMCDDA founding regulation | New products and services | EMCDDA Director pays official visit to Europol
Following the success of the First European conference on addictive behaviours and dependencies in 2015, the organisers are pleased to announce Lisbon Addictions 2017, to be held in the Portuguese capital from 24–26 October 2017.
The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces next summer to hold the sixth European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’.
Vytenis Andriukaitis, European Commissioner for Health and Food Safety, will visit the EMCDDA today for an update on the agency’s work in the area of public health.
EMCDDA Director Alexis Goosdeel is paying an official visit to Europol today where he will discuss with Director Rob Wainwright opportunities for further cooperation between the two agencies.
Contingency management is a general behavioural intervention technique used in the treatment of drug dependence. This EMCDDA Paper contains a systematic review of studies on the effectiveness of contingency management when used alongside the pharmacological treatment of dependence. The 38 studies concerned related to people using various drugs, and were complemented by three economic studies. The analysis contained in the Paper concludes that contingency management is a feasible and promising adjunct to treatment for drug users.
Ahead of World Mental Health Day on 10 October, the EMCDDA has published a new review on how contingency management can help treat those with substance use disorders.
The third group of students graduating from the European Masters in Drug and Alcohol Studies (EMDAS), will receive their diplomas at a ceremony at the EMCDDA on 23 September.
This brochure provides an overview of the 2015 ESPAD Report which the EMCDDA co-produced with ESPAD.
This report presents the most recent and comprehensive data on substance use among 15- to 16-year-old school students in Europe. Based on the responses from over 90 000 girls and boys, the report documents the levels of use of tobacco, alcohol, cannabis and other substances, as well as the frequency of a number of potentially addictive behaviours, such as online gambling, in 35 European countries. The report also looks at changes in substance use over the past 20 years and at gender differences in substance use and internet behaviour.
Smoking and drinking among 15–16-year-old school students are showing signs of decline, but there are concerns over challenges posed by new drugs and new addictive behaviours.
The latest European data on substance use among 15–16-year-old school students will be released next week (20 September). The findings are based on a 2015 survey in 35 European countries
The Director will present the European Drug Report 2016 on 8 September 2016 to the members of the Civil Liberties, Justice and Home Affairs (LIBE) Committee of the European Parliament. The presentation is scheduled from 15.30 to 16.20 (Brussels times). Live streaming will be availalbe on the website of the European Parliament: www.europarl.europa.eu/ep-live/en/committees/video?event=20160908-1400-COMMITTEE-LIBE
This brochure offers an overview of the latest EU Drug Markets Report, from the EMCDDA and Europol. Published every three years, the report provides a state-of-the-art analysis of the illicit drug market, covering trends along the supply chain from production and trafficking to marketing, distribution and consumption. The report combines the EMCDDA’s drug monitoring and analytical capacity with Europol’s operational intelligence on trends in organised crime.
Today, the European Commission has proposed to subject the new psychoactive substance MDMB-CHMICA (sometimes referred to as ‘Black Mamba’) to control measures across the European Union.
This rapid communication provides an update on drug related hospital emergency presentations in Europe with a specific focus on the latest results for acute drug toxicity presentations to the European Drug Emergencies Network (Euro-DEN). This report is primarily based on presentations and discussions at a two-day meeting of the Euro-DEN Plus network in Lisbon on 7 and 8 April 2016. The meeting provided a platform for the presentation of new analyses from the Euro-DEN dataset, and further development and analyses of the Euro-DEN project were also discussed.
Data from hospital emergency departments show that every year in Europe thousands of individuals experience drug-related poisoning and other harms, requiring some kind of medical assistance.
Hepatitis C among drug users in Europe: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state-of-the-art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene.
Hepatitis C is an infectious disease of the liver caused by the blood-borne hepatitis C virus. In a new report published today on World Hepatitis Day, the EU drugs agency (EMCDDA) looks at new opportunities for the effective prevention and treatment of hepatitis C.
This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 June 2016, the Council decided that α-PVP should be subject to control measures across the Member States.
Members of the European Parliament Committee on Civil Liberties, Justice and Home Affairs (LIBE) start a two-day visit to the EMCDDA today where they will hear presentations on the agency’s contribution to a more secure and a healthier Europe.
This report presents the key activities performed by the EMCDDA and Europol in 2015 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2015, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network.
EMCDDA Director Alexis Goosdeel is in Berlin today where he is speaking at a public hearing at the German Parliament (Bundestag) on the issue of new psychoactive substances (NPS). The hearing is organised by the Bundestag Health Committee and chaired by Dr Edgar Franke (Member of the German Parliament).
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDMB-CHMICA as stipulated by Article 5.1 of the Council Decision.
These are the EMCDDA's final annual accounts for the financial year 2015.
The EU drugs agency (EMCDDA) is hosting a conference in Lisbon today marking the end of a 30-month technical cooperation project within the framework of the European Neighbourhood Policy (ENP).
In this issue: European Drug Report 2016 highlights | Return of MDMA | Rises in overdose deaths | Health responses to new psychoactive substances | Gold medal for EMCDDA | World hepatitis day | New EMCDDA products and services | 2016 EMCDDA scientific paper award
The fifth European drugs summer school — ‘Illicit drugs in Europe: demand, supply and public policies’ — opened today in Lisbon and will run until 8 July. The initiative, organised by ISCTE and the EMCDDA, is supported by NIDA.
The emergence of new psychoactive substances (NPS) over the last decade has posed a major challenge to drug policy. While the limited available data indicates that prevalence levels of NPS use are relatively low in the general European population, there are concerns around more problematic forms of use and harms in particular drug using populations. A number of public health concerns have arisen as a consequence of their use, although the real extent of these harms across Europe remains unknown.
While prevalence levels of NPS use remain low in the general European population, there are important concerns with more problematic forms of use and harms. This short report provides an overview of the current situation in terms of NPS use and harms across Europe and reviews the available health- and drug-related interventions in that area.